Inventor
LA PORTE SHERRY LYNN
US10 patents
⚠️ This page may combine multiple inventors who share the name “LA PORTE SHERRY LYNN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CYTOMX THERAPEUTICS INC
7 patentsUS9309510B2Apr 12, 2016
Protease-resistant systems for polypeptide display and methods of making and using thereof
CYTOMX THERAPEUTICS INC26 citations93
US10669337B2Jun 2, 2020
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
CYTOMX THERAPEUTICS INC31 citations89
US11161906B2Nov 2, 2021
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CYTOMX THERAPEUTICS INC12 citations82
US12139816B2Nov 12, 2024
Protease-resistant systems for polypeptide display and methods of making and using thereof
CYTOMX THERAPEUTICS INC0 citations62
US11198864B2Dec 14, 2021
Protease-resistant systems for polypeptide display and methods of making and using thereof
CYTOMX THERAPEUTICS INC0 citations62
US10947531B2Mar 16, 2021
Protease-resistant systems for polypeptide display and methods of making and using thereof
CYTOMX THERAPEUTICS INC0 citations62
US11802158B2Oct 31, 2023
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
CYTOMX THERAPEUTICS INC1 citations58
JANSSEN BIOTECH INC
3 patentsUS12084501B2Sep 10, 2024
Proteins comprising CD3 antigen binding domains and uses thereof
JANSSEN BIOTECH INC2 citations66
US12077585B2Sep 3, 2024
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
JANSSEN BIOTECH INC0 citations58
US12460001B2Nov 4, 2025
Proteins comprising CD3 antigen binding domains and uses thereof
JANSSEN BIOTECH INC0 citations54